Bio-Techne Corporation (NASDAQ:TECH) Q4 2025 Earnings Call Transcript
Operator: Good morning, and welcome to Bio-Techne's Earnings Conference Call for the Fourth Quarter and Fiscal Year 2025.
Bio-Techne Corp (TECH)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Montanaro Asset Management Charles Montanaro | 294,950 | $15,175,178 | +15% | 3.91% |
| 2. | Bayforest Capital Theodoros Tsagaris | 4,628 | $238,111 | +2% | 0.1% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $352.55 | 300 | $105,765.00 | 10,106 | 2022-05-10 | Filing | |
| $185.00 | 100 | $18,500.00 | 100 | 2019-09-09 | Filing | |
| $185.00 | 100 | $18,500.00 | 100 | 2019-09-09 | Filing | |
| $191.06 | 500 | $95,530.00 | 8,726 | 2019-08-07 | Filing | |
| $65.00 | 2,361 | $153,465.00 | 70,000 | 2013-05-06 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $49.77 | 1,280 | $63,704.83 | 1,976 | 2025-06-09 | Filing | |
| $65.96 | 1,860 | $122,690.62 | 1,976 | 2025-02-14 | Filing | |
| $77.95 | 1,661 | $129,479.93 | 39,004 | 2025-01-27 | Filing | |
| $77.19 | 11,731 | $905,533.49 | 40,665 | 2025-01-27 | Filing | |
| $72.10 | 16,000 | $1,153,664.00 | 43,401 | 2024-08-08 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,349,712 | $120,892,682 | 0.08% | |
| 2. | 1,923,092 | $98,943,084 | 0.02% | |
| 3. | 1,185,099 | $60,973,359 | 1.02% | |
| 4. | 972,085 | $50,013,773 | 0.13% | |
| 5. | 954,889 | $49,129,046 | 0.79% |
News See All
Bio-Techne Corporation (TECH) Slid on Weakness in Research Spending
Baron Funds, an investment management company, released its “Baron Asset Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S.
Bio-Techne Corporation (TECH) Slid on Rise in Investors’ Concerns
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” second quarter 2025 investor letter. A copy of the letter can be downloaded here.
Bio-Techne Corporation (TECH) Gets Initiated With a New Buy Rating at TD Cowen
Bio-Techne Corporation (NASDAQ:TECH) is one of the most profitable biotech stocks to invest in now.
10 Most Profitable Biotech Stocks to Invest in Now
Jared Holz, Mizuho health care equity strategist, appeared on CNBC’s 'Power Lunch' on March 5 to talk about investing in biotech and the oversaturation in the sector.
Bio-Techne Corporation (TECH): A Bull Case Theory
We came across a bullish thesis on Bio-Techne Corporation on Stock Analysis Compilation’s Substack. In this article, we will summarize the bulls’ thesis on TECH.
Here’s Headwaters Capital Management’s Investment Thesis for Bio-Techne (TECH)
Headwaters Capital Management, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Bio-Techne, USP Partner to Enhance Monoclonal Antibody, Gene Therapy Development
Bio-Techne Corporation (NASDAQ:TECH) is one of the best S&P 500 stocks with huge upside potential. On June 24, Bio-Techne Corporation announced a distribution agreement with the US Pharmacopeia/USP.
12 Best S&P 500 Stocks With Huge Upside Potential
Bankim Chadha, Deutsche Bank's chief global strategist, joined CNBC's 'The Exchange' on June 24 to express a cautionary view regarding further monetary policy movement despite recent positive inflation...
Here’s What Pulled Down Bio-Techne Corporation (TECH)
Baron Funds, an investment management company, released its “Baron Asset Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. After a strong start to 2025, U.S.
Billionaire Hedge Funds
